Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: Comparison with methylation-specific PCR technique and clinical significance

Molecular Medicine Reports

Volumn 5, Issue 1, 2012, Pages 239-244

  Lee, Su Man ^a   Lee, Won Kee ^a   Kim, Dong Sun ^a   Park, Jae Yong ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Lung cancer; Methylation; Methylation specific PCR; Pyrosequencing; RASSF1A; Survival outcome

Indexed keywords

PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN METHYLATION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; QUANTITATIVE PROMOTER HYPERMETHYLATION ANALYSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; SMOKING; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

PYRONIA TITHONUS;

EID: 84855221091     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.608     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Minna JD, Roth JA and Gazdar AF: Focus on lung cancer. Cancer Cell 1: 49-52, 2002. (Pubitemid 41039175)
3. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000. (Pubitemid 30169152)
4. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006. (Pubitemid 43361543)
5. Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 1-11, 2004.
6. Tsou JA, Hagen JA, Carpenter CL and Laird-Offringa IA: DNA hypermethylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21: 5450-5461, 2002. (Pubitemid 34983481)
7. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y and Motoyama T: Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 94: 589-592, 2003. (Pubitemid 36975012)
8. Alberg AJ, Brock MV and Samet JM: Epidemiology of lung cancer: looking to the future. J Clin Oncol 23: 3175-3185, 2005. (Pubitemid 46217457)
9. Shames DS, Minna JD and Gazdar AF: Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 251: 187-198, 2007. (Pubitemid 46669792)
10. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SD: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
11. Colella S, Shen L, Baggerly KA, Issa JP and Krahe R: Sensitive and quantitative universal pyrosequencing methylation analysis. Biotechniques 35: 152-156, 2003.
12. Agathanggelou A, Cooper WN and Latif F: Role of the Ras-association domain family 1 tumor-suppressor gene in human cancers. Cancer Res 65: 3497-3508, 2005. (Pubitemid 40616319)
13. Hesson LB, Cooper WN and Latif F: The role of RASSF1A methylation in cancer. Dis Markers 23: 73-87, 2007. (Pubitemid 46333640)
14. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier, K and Pfeifer GP: The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20: 645-663, 2005. (Pubitemid 40468282)
15. Vaissiere T, Hung RJ, Zaridze D, et al.: Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 69: 243-252, 2009.
16. Kim DS, Kim MJ, Lee JY, Kim YZ, Kim EJ and Park JY: Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopahological features. Cancer 110: 2785-2792, 2007.
17. Burbee DG, Forgacs E, Zochbauer-Muller S, et al.: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001. (Pubitemid 32492810)
18. Tomizawa Y, Kohno T, Kondo H, et al.: Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 8: 2362-2368, 2002. (Pubitemid 34753611)
19. Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han H and Park J: Hypermethylation of promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63: 3743-3746, 2002.
20. Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS and El-Naggar AK: Quantitative promoter hypermethylation analysis of cancer-related genes in salivary carcinomas: comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res 14: 2644-2672, 2008.
21. Shaw RJ, Hall GL, Lowe D, et al.: CpG island methylation phenotype (CIMP) in oral cancer: association with a marked inflammatory response and less aggressive tumour biology. Oral Oncol 43: 878-886, 2007. (Pubitemid 47369250)